Key takeaways
Premiums reflect lockout cost. Boston Scientific, Thermo Fisher, GSK, and J&J each paid for competitive positioning that would take years to replicate organically—often exceeding what current earnings would justify.
Scarcity and deal activity aren't the same. High transaction volume doesn't indicate limited supply. The test is whether one or two more deals would close the category to new entrants.
The buyer universe has expanded beyond traditional strategics. Pharma distributors are now acquiring physician platforms for clinical access, broadening exit optionality for sponsor-owned assets.
Waiting carries category-specific risk. In consolidating categories, additional scale may matter less than whether buyer interest persists after competitors complete their positioning.
What strategic healthcare M&A reveals about shrinking optionality
The healthcare M&A landscape shifted meaningfully in the final quarter—four major deals signal where strategics believe the category battles will be significant:
Boston Scientific's $14.5 billion acquisition of Penumbra.
Thermo Fisher's $9.4 billion move on Clario.
GSK paying a 65% premium for RAPT Therapeutics.
J&J closing Shockwave at $13.1 billion.
Each deal carried different strategic rationale: vascular leadership, clinical trial infrastructure, pipeline optionality, standard-of-care positioning. However, they share a common feature: the acquirer priced what it would cost to be locked out, which often exceeded what the target currently earns. That valuation logic has implications for every independent asset sitting in adjacent categories.
What the premiums actually price
The $191 billion in healthcare PE deal value last year indicates where strategics are concentrating bids and what that reveals about which categories they believe cannot be replicated organically.
When Thermo Fisher pays 7x revenue for Clario (a clinical software company), it's actually buying the 70% market position in FDA approval support that would take a decade to build. The premium reflects years of execution they cannot afford to spend.
Pharma faces a similar calculus. With $230 billion in projected US revenue losses from patent expirations between 2025 and 2030, companies like GSK are paying substantial premiums for Phase II assets before clinical proof because waiting means watching competitors lock up the pipeline first. RAPT's food allergy candidate isn't proven. But GSK decided that the cost of being right and late exceeded the cost of being early and wrong.
Medtech deal value surged to $97.6 billion in 2025, the highest in more than a decade. Activity concentrated in cardiovascular, surgical robotics, and diagnostics―categories where clinical evidence, regulatory approval, and payor relationships create barriers that capital alone cannot overcome quickly.
Three questions that separate "attractive" from "irreplaceable"
The difference between a competitive process and a bidding war often comes down to whether the asset controls something that cannot be rebuilt on a reasonable timeline. Pressure-testing that distinction typically comes down to three considerations.
If a competitor owned this tomorrow, what would you have to build?
If the answer is "a decade of clinical evidence" or "70% of FDA relationships," you're looking at scarcity. If the answer is "a sales team and 18 months," you're not. Penumbra's position in thrombectomy falls into the first category. Most healthcare IT platforms fall into the second one.
Is the category consolidating toward one or two owners, or fragmenting into specialists?
Thrombectomy is consolidating. Revenue cycle management is fragmenting. The valuation logic differs accordingly. In consolidating categories, the next deal may be the last chance to buy in. In fragmenting categories, alternatives will continue to emerge.
Would a strategic pay more to own this or to deny it to a competitor?
When the defensive value exceeds the offensive value, scarcity dynamics apply. J&J acquired Shockwave largely to prevent a competitor from owning the emerging standard of care in cardiovascular treatment—a defensive rationale that justified the premium.
The buyer universe has expanded
Cardinal Health, Cencora, and McKesson have collectively acquired four physician platforms in eighteen months. Distributors buying clinical access represents a new category of strategic buyer that didn't exist for sponsors five years ago and reframes which assets have exit optionality beyond traditional PE-to-PE or PE-to-strategic paths.
Sales to strategics jumped 26% in number and more than doubled in value in early 2025. When strategics compete, premiums follow. But timing carries risk that isn't always visible in the data.
Each strategic acquisition removes an independent asset from the market. What happens next varies: sometimes competitors accelerate their own M&A activity to keep pace; other times, a strategic that completes one deal may deprioritize adjacent targets, having addressed their category needs.
For sponsor-owned assets, determining which dynamic applies (and whether waiting clarifies the picture or simply narrows the options) requires category-specific judgment.
Where scarcity is real vs. overstated
Cardiovascular devices are consolidating fast. Boston Scientific, J&J, and Medtronic have each made platform moves, and independent assets in thrombectomy and structural heart are thinning. But behavioral health, despite high deal volume, remains fragmented with multiple scaled platforms and no clear category owner emerging. Activity isn't scarcity.
Five categories worth watching
These are categories where one or two more deals would leave few independent assets remaining.
Neurovascular intervention. Boston Scientific's Penumbra acquisition narrows the field significantly. Remaining independent assets face a shrinking buyer universe as the major players complete their positioning.
Clinical trial endpoint infrastructure. Thermo Fisher now owns the dominant platform. CRO adjacencies and real-world evidence capabilities face similar dynamics as pharma and biotech companies evaluate build-vs-buy decisions for trial support.
Specialty pharma pipelines. GSK, Pfizer, and others are shopping to offset projected revenue losses from patent expirations. Phase II and III assets in immunology, oncology, and rare disease are targets, particularly those with differentiated mechanisms or first-mover positioning in emerging therapeutic categories.
Procedure-heavy physician specialties. GI, urology, ophthalmology, and oncology platforms with clinical integration and ancillary services are attracting both PE and strategic interest. Distributor acquisitions signal that control of specialty drug utilization and site-of-care decisions carries strategic value beyond traditional practice economics.
Healthcare IT enabling clinical workflows. Deal value in healthcare IT doubled to $32 billion in 2025, but fragmentation limits scarcity dynamics to specific niches—AI-driven clinical decision support being one where consolidation is more advanced.
What this means for your positioning
For investors holding healthcare assets, the shift from consolidation to scarcity has the following implications:
Valuation frameworks need adjustment.
Instead of focusing on cash flow-based worth, ask, "what would it cost a competitor to be locked out of this category?" That's a different calculation, and it requires understanding buyer motivations beyond financial returns.
Timing carries asymmetric risk.
Waiting for further scale may reduce strategic urgency if competitors acquire substitutes first. The traditional logic of building more value before exit assumes the buyer universe remains constant. But when Cardinal Health, Cencora, and McKesson each complete their physician platform acquisitions, the pool of motivated buyers for remaining assets narrows accordingly.
Competitive intelligence matters more.
When a strategic acquires a peer or adjacent asset, the landscape shifts. Mapping how recent deals affect buyer interest and urgency for remaining independent assets should be an ongoing exercise.
Engagement timing may need to move earlier.
Engagement timing may need to move earlier. If an asset has genuine scarcity characteristics, outreach to potential acquirers before a formal process may surface interest and improve positioning.
Positioning should reflect strategic value.
For assets with exit potential to strategics, investor materials should emphasize competitive moat, clinical pathway importance, and what ownership provides that cannot be replicated. Financial performance matters, but it may not be the primary driver of strategic interest.
Bottom line
The strategic acquisitions of the past ninety days have clarified something that wasn't obvious six months ago: in certain healthcare categories, the competitive map is being redrawn faster than most participants expected.
For investors and advisors holding independent assets in consolidating categories, building more scale or waiting for better multiples may matter less than whether the asset will still attract the same buyer interest twelve months from now.
